康宁杰瑞制药-B早盘涨超6% HER2双抗KN026III期临床获批

新浪港股
25 Oct 2024
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  康宁杰瑞制药-B(09966)早盘上涨6.09%,现报4.01港元,成交额1292.73万港元。

  近日,康宁杰瑞生物制药与石药集团共同宣布,HER2双特异性抗体KN026联合白蛋白结合型多西他赛HB1801的一项Ⅲ期临床研究(研究方案号:KN026-004)申请已获得国家药品监督管理局(NMPA)药品审评中心(CDE)批准,用于HER2阳性早期或局部晚期乳腺癌的新辅助治

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10